Nevro Corp. (NYSE:NVRO) Director Wilfred E. Jaeger sold 52,520 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $86.11, for a total value of $4,522,497.20. Following the completion of the sale, the director now owns 1,518 shares of the company’s stock, valued at $130,714.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Wilfred E. Jaeger also recently made the following trade(s):

  • On Tuesday, August 15th, Wilfred E. Jaeger sold 29,665 shares of Nevro Corp. stock. The shares were sold at an average price of $82.54, for a total value of $2,448,549.10.
  • On Monday, August 14th, Wilfred E. Jaeger sold 25,255 shares of Nevro Corp. stock. The shares were sold at an average price of $82.40, for a total value of $2,081,012.00.
  • On Wednesday, August 16th, Wilfred E. Jaeger sold 79,657 shares of Nevro Corp. stock. The shares were sold at an average price of $82.74, for a total value of $6,590,820.18.

Shares of Nevro Corp. (NVRO) traded up 0.42% during trading on Thursday, hitting $86.36. The stock had a trading volume of 323,628 shares. The company’s market cap is $2.54 billion. Nevro Corp. has a 12-month low of $65.82 and a 12-month high of $106.93. The stock’s 50 day moving average is $84.55 and its 200-day moving average is $85.06.

Nevro Corp. (NYSE:NVRO) last posted its earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.11. The business had revenue of $78.02 million for the quarter, compared to analyst estimates of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The company’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.31) earnings per share. Analysts forecast that Nevro Corp. will post ($1.16) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/24/nevro-corp-nvro-director-sells-4522497-20-in-stock.html.

Several equities analysts have recently commented on the company. B. Riley lowered Nevro Corp. from a “buy” rating to a “neutral” rating and decreased their price target for the company from $108.00 to $85.00 in a research note on Tuesday, May 9th. Morgan Stanley upped their price target on Nevro Corp. from $87.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, August 8th. Northland Securities reaffirmed a “buy” rating and issued a $96.00 price target on shares of Nevro Corp. in a research note on Tuesday, August 8th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $102.00 price target on shares of Nevro Corp. in a research note on Monday, July 3rd. Finally, Zacks Investment Research lowered Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Saturday, June 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $100.57.

Institutional investors have recently bought and sold shares of the company. Fortaleza Asset Management Inc. acquired a new stake in shares of Nevro Corp. during the first quarter valued at about $164,000. Ameritas Investment Partners Inc. increased its stake in shares of Nevro Corp. by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $181,000 after buying an additional 358 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Nevro Corp. by 118.8% in the first quarter. Tower Research Capital LLC TRC now owns 1,943 shares of the medical equipment provider’s stock valued at $182,000 after buying an additional 1,055 shares in the last quarter. PNC Financial Services Group Inc. acquired a new stake in shares of Nevro Corp. during the second quarter valued at about $190,000. Finally, US Bancorp DE increased its stake in shares of Nevro Corp. by 412.4% in the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 2,099 shares in the last quarter.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.